Source comparison
MOTS-c Safety: Clinical vs Research-Grade Comparison
Purity Standard ≥98% via HPLC ≥95% via HPLC (verified suppliers) or unverified Research-grade from verified suppliers matches clinical purity; unverified sources carry contamination risk that compounds over long-term use Endotoxin Limit <0.05 EU/mg (FDA standa
This comparison does not assign a generated winner or score.
- Purity Standard
- ≥98% via HPLC
- ≥95% via HPLC (verified suppliers) or unverified
- Research-grade from verified suppliers matches clinical purity; unverified sources carry contamination risk that compounds over long-term use
- Endotoxin Limit
- <0.05 EU/mg (FDA standard)
- <0.1 EU/mg (reputable suppliers) or untested
- Chronic low-level endotoxin exposure is the primary long-term safety concern with research peptides. Verified suppliers mitigate this
- Batch Consistency
- Pharmaceutical GMP oversight
- Varies by supplier; third-party COA required
- Batch-to-batch variation in potency can lead to unintended dose escalation or inconsistent metabolic signaling over time
- Storage & Handling
- Pre-filled syringes, cold-chain verified
- Lyophilized powder requiring reconstitution
- Improper reconstitution or storage above 8°C degrades peptide structure; stability loss is cumulative over months
- Long-Term Human Data
- Phase 2 trials (max 12 months)
- None. Research use only
- Neither category has multi-year human safety data; the distinction is purity assurance, not proven long-term safety
- Cost per Month (15mg/week)
- $600–$1,200/month
- $180–$350/month
- Lower cost can incentivize extended unsupervised use; higher cost doesn't guarantee better long-term outcomes without proper monitoring